Trimodulin - Biotest

Drug Profile

Trimodulin - Biotest

Alternative Names: BT 588; BT086; IgM concentrate - Biotest

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biotest AG
  • Class Antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Community-acquired pneumonia

Most Recent Events

  • 03 Nov 2017 Efficacy data from a phase II trial in severe community-acquired pneumonia released by Biotest (Biotest pipeline, November 2017)
  • 03 Nov 2017 Biotest plans a phase III trial for severe community-acquired pneumonia (Biotest pipeline, November 2017)
  • 01 Apr 2015 Biotest AG completes a phase) II trial in Community acquired pneumonia (Adjunctive therapy) in United Kingdom, Belgium, Spain and Germany (NCT01420744)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top